Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity

Lenalidomide-Induced Immunomodulation in Multiple Myeloma: Impact on Vaccines and Antitumor Responses

(2012) Kimberly Noonan et al.   CLINICAL CANCER RESEARCH

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

(2012) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

(2012) Michel Attal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

(2012) Philip L. McCarthy et al.   NEW ENGLAND JOURNAL OF MEDICINE

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

(2011) P. Fenaux et al.   BLOOD

Pharmacokinetics, metabolism and excretion of [14C]-lenalidomide following oral administration in healthy male subjects

(2011) Nianhang Chen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Lenalidomide in multiple myeloma: current role and future directions

(2010) Jerome B Zeldis et al.   EXPERT OPINION ON PHARMACOTHERAPY

Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma

(2010) Shinsuke Iida et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias

(2010) William Blum et al.   JOURNAL OF CLINICAL ONCOLOGY

Distribution of Lenalidomide Into Semen of Healthy Men After Multiple Oral Doses

(2010) Nianhang Chen et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism

(2009) L. Escoubet-Lozach et al.   CANCER RESEARCH

Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

(2009) Thomas E. Witzig et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Oral Lenalidomide in Patients With Refractory Metastatic Cancer

(2009) William L. Dahut et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

(2009) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

(2009) M A Dimopoulos et al.   LEUKEMIA

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

(2008) A. Ferrajoli et al.   BLOOD

Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells

(2008) L. Wu et al.   CLINICAL CANCER RESEARCH

Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

(2008) Peter H. Wiernik et al.   JOURNAL OF CLINICAL ONCOLOGY